VITA 34 AG (V3V) fair value: what the stock is really worth
As of Sep 28, 2026: fair value of VITA 34 AG €3.15, price €2.96, upside +6.4%, quality 41 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch VITA 34 AG for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 27, 2026.
How to read this chart
60‑month range €2.68 – €17.30 · fair‑value band €2.20 – €4.11 · the €2.96 price screens below the €3.15 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. Dashed = 300-day average. As of Sep 27, 2026.
Follow VITA 34 in your weekly email
Every Wednesday you see whether VITA 34 is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
FamiCord AG engages in the collection, processing, storage, and distribution of cells, tissues, blood, and blood components for medical applications in Germany, Poland, Switzerland, Portugal, and internationally. The company operates through Subgroup Vita 34 And Subgroup PBKM segments.
Show more
FamiCord AG engages in the collection, processing, storage, and distribution of cells, tissues, blood, and blood components for medical applications in Germany, Poland, Switzerland, Portugal, and internationally. The company operates through Subgroup Vita 34 And Subgroup PBKM segments. It produces and develops advanced therapies, genetic tests, and analyses for third parties. The company also engages in the development and manufacture of cell and tissue-based products and pharmaceuticals, including the production of viral vectors or comparable products. In addition, it engages in research and development, storage, and cryopreservation of sperm and oocytes for use in reproductive medicine; and the manufacturing and distribution of medical devices. The company was formerly known as VITA 34 AG and changed its name to FamiCord AG in February 2025. FamiCord AG was founded in 1997 and is headquartered in Leipzig, Germany.
Stock analysis
VITA 34 AG (V3V) currently trades at €2.96, while our model-based Fair Value estimate is €3.15, so the stock looks roughly fairly valued today (gap 6.0%).
Show more
Valuation
How firm this estimate is: it rests on 3 models at a data quality of 93/100, which puts the evidence level at low.
Scenario range: €2.20 (bear) to €4.11 (bull), the price of €2.96 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 41/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
VITA 34 AG reported revenue of €88.2M in FY2025 versus €28.4M in FY2021, a compound +32.7%/yr. Reported net income was −€6.3M in FY2025.
Key figures
Market cap €51.6M · P/S ratio 0.60 · EPS (TTM) €−0.2600 · Net margin −7.1% · Return on equity −56.8% · Return on assets (EBIT) −5.8% · Operating margin 0.9% · Revenue (TTM) €87.6M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).
What moves the price
The share trades about 57% below its 52-week high and 10% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 21% fair-value upside, at 6%, V3V screens richer than that median.
Fair Value models
Bear €2.20Fair Value €3.15Bull €4.11
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.44/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+7.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+34.4%
Start year 2020 (pandemic). Over 10 years: +20.1% a year
Revenue growth 18 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.2%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
11.9% (2020) → −4.0% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 251 stocks
Beats the industry median on 3/10 measures
Overall it trails its industry peers.
Valuation
Quality Score41 · Bottom 25%
Fair Value upside+6.4% · Above median
Profitability
Return on assets0.7% · Bottom 25%
Net margin (TTM)−6.7% · Bottom 25%
Operating margin (TTM)0.9% · Bottom 25%
Growth and dividend
Revenue growth−2.7% · Bottom 25%
Balance sheet
Debt / equity1.55× · Highest 25%
Valuation Multiplesvs Medical Care Facilities median · lower = cheaper
P/B8.24× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "VITA 34 AG Fair Value". https://www.fairvalue-calculator.com/stock/V3V
Frequently asked questions
Is VITA 34 AG (V3V) overvalued or undervalued?
As of Sep 27, 2026, our model estimates a fair value of €3.15 versus a price of €2.96, about +6% upside (fairly valued).
What is the fair value of V3V?
Our model-based fair value for VITA 34 AG is €3.15 (as of Sep 27, 2026), built from audited fundamentals. The current price: €2.96.
What is the quality score of V3V?
VITA 34 AG has a Quality Score of 41/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for VITA 34 AG (V3V)?
Our model-based price target is the fair value of €3.15 (as of Sep 27, 2026) from 2 valuation models. Cautious scenario €2.20, optimistic scenario €4.11. It is a calculation from audited fundamentals, not an analyst target.
What is the VITA 34 AG stock forecast for 2026?
Our models put fair value at €3.15, about +6% upside versus a price of €2.96 (fairly valued). Cautious scenario €2.20, optimistic scenario €4.11. The calculation is refreshed regularly with new filings.
What is the revenue of VITA 34 AG (V3V)?
VITA 34 AG reported trailing-twelve-month revenue of about €87.6M (latest available figure, as of Sep 27, 2026).
What is the intrinsic value of VITA 34 AG (V3V)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For VITA 34 AG it is €3.15 per share (as of Sep 27, 2026), against a price of €2.96. It is the blended result of 2 valuation models (cash flow, earnings, asset, dividend).
Is VITA 34 AG stock overvalued or undervalued in 2026?
As of Sep 27, 2026, V3V trades below its calculated fair value: price €2.96, fair value €3.15, a gap of about +6% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of V3V?
No. The price is what the market pays today (€2.96); the fair value is what the company's own numbers justify (€3.15). For VITA 34 AG the two are €0.1900 per share apart. That gap is exactly why we show both numbers side by side.
How much is VITA 34 AG worth?
The market values VITA 34 AG at about €51.6M (market capitalisation, as of Sep 27, 2026). Per share that is €2.96; our models calculate a fair value of €3.15 per share.
What do the bullish and bearish scenarios say about V3V?
Our models span a range for VITA 34 AG: cautious scenario €2.20, base €3.15, optimistic €4.11 per share (as of Sep 27, 2026, price €2.96). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the PEG ratio of V3V?
The PEG ratio of VITA 34 AG is 3.98 (P/E divided by earnings growth, as of Sep 27, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of VITA 34 AG (V3V)?
Balance-sheet figures for VITA 34 AG (as of Sep 27, 2026): return on equity −56.8%, debt of 1.55 per unit of equity. They feed the Quality Score of 41/100, which measures business quality independently of the share price.
How far is V3V from its 52-week high?
VITA 34 AG trades at €2.96, about 57% below its 52-week high of €6.85 and 10% above the low of €2.68 (as of Sep 28, 2026). Distance from the high says nothing about value: that is what the fair value of €3.15 is for.
Which stocks are comparable to VITA 34 AG?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Dr. Sulaiman Al Habib Medical Services Group, Tenet Healthcare Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is VITA 34 AG stock attractive at the current price?
The data as of Sep 27, 2026: price €2.96, calculated fair value €3.15 (+6%), Quality Score 41/100, from 2 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of V3V calculated?
We run VITA 34 AG through 2 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of €3.15, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.9 % above its aggregate fair value. VITA 34 AG currently trades 6 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of VITA 34 AG (V3V)?
The closing price on Sep 28, 2026 was €2.96. Our model-based fair value is €3.15, about +6% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with VITA 34 AG right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. A fairly wide model range (€2.20 to €4.11) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of VITA 34 AG
How large is the market capitalisation of VITA 34 AG (V3V)?
The market capitalisation of VITA 34 AG is €51.6M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of VITA 34 AG (V3V)?
The price-to-sales ratio of VITA 34 AG is 0.60 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of VITA 34 AG (V3V)?
Earnings per share at VITA 34 AG are €−0.2600. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of VITA 34 AG (V3V)?
The net margin of VITA 34 AG is −7.1% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of VITA 34 AG (V3V)?
The return on equity (ROE) of VITA 34 AG is −56.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of VITA 34 AG (V3V)?
On an EBIT basis the return on assets of VITA 34 AG is −5.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of VITA 34 AG (V3V)?
The operating margin of VITA 34 AG is 0.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at VITA 34 AG (V3V)?
Revenue at VITA 34 AG is growing −2.7% versus a year earlier (3y avg +8.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at VITA 34 AG (V3V)?
Earnings per share at VITA 34 AG are growing −12.5% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does VITA 34 AG (V3V) generate?
The free cash flow of VITA 34 AG is −€249K (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does VITA 34 AG (V3V) carry?
The net debt of VITA 34 AG is €11.6M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch VITA 34 AG in the live analysis
One click puts VITA 34 AG on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
